Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis

Video

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

CancerNetwork® had the opportunity to speak with Efstathios Kastritis, MD, at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting. The professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, detailed the overall takeaway of the phase 3 ANDROMEDA trial (NCT03201965), specifically how treatment with daratumumab (Darzalex) plus bortezomib, cyclophosphamide, and dexamethasone (VCd) improved outcomes for patients with newly diagnosed light chain (AL) amyloidosis.

Transcription:

We do have a very effective and relatively safe therapy for patients with AL amyloidosis, which has really and substantially improved the outcomes of our patients, [with] both complete hematologic response rates and organ responses, which is actually the ultimate goal of therapy in these patients. I really expect that this will be translated in an improvement in the overall survival in the follow up of this study.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 8003.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content